Shares of Nektar Therapeutics (NASDAQ:NKTR) gained on Friday after Jefferies upgraded the stock noting an attractive ...

The company has lost over 63% of its market value in the past six months, but Jefferies analyst Roger Song cited encouraging ...

Virtual Meeting to be held on April 22-23 hosted by B. Riley.Stay Ahead of the Market: Discover outperforming stocks and invest smarter with ...

It has been about a month since the last earnings report for Nektar Therapeutics (NKTR). Shares have lost about 38.8% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) has been assigned a consensus recommendation of “Buy” from the seven analysts that are currently covering the stock, Ratings reports. One equities ...

Nektar Therapeutics’s NKTR share price has surged by 18.21%, which has investors questioning if this is right time to sell.

Jefferies upgraded Nektar (NKTR) to Buy from Hold with a price target of $2, up from $1. The company’s rezpegaldesleukin will report topline ...

In this article, we are going to take a look at where Nektar Therapeutics (NASDAQ:NKTR) stands against other stocks that Wall Street is calling bullish amid market turmoil. The S&P 500 is down 8.6 ...

Zacks Research boosted their Q1 2025 earnings per share estimates for Nektar Therapeutics in a research note issued on ...

Chante Moore is set to perform today at 8 p.m. at the Kewsick Theatre in Glenside. Moore’s music is at once sensuous, ...

With Takeda’s £46 billion acquisition of Shire, it’s been a busy year for pharma M&A – and according to analysts Datamonitor, the specialist biotechs Nektar, BioMarin and Alnylam are the ...

Nektar Therapeutics (NKTR) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to loss of $0.22 per share a year ago.